Royalty Pharma plc RPRX
Royalty Pharma plc (Nasdaq: RPRX) is a life-science royalty company. Its next catalyst on record is Neladalkib (Nuvalent/GSK; royalty-funded candidate): FDA PDUFA date (licensee-sponsored) (November 27, 2026).
Upcoming catalysts
- November 27, 2026Neladalkib (Nuvalent/GSK; royalty-funded candidate) — FDA PDUFA date (licensee-sponsored)
In May 2026, Nuvalent announced the FDA accepted its NDA for neladalkib for filing and granted the application Priority Review with a PDUFA date of November 27, 2026.
- April 23, 2027Deucrictibant (Pharvaris; royalty-funded candidate) — FDA PDUFA date (licensee-sponsored)
In July 2026, Pharvaris announced that the FDA accepted its NDA for deucrictibant immediate-release for the on-demand treatment of hereditary angioedema attacks and assigned a PDUFA date of April 23, 2027.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Royalty on Vertex cystic fibrosis franchise (Trikafta, Alyftrek and others) | Cystic fibrosis | small molecule | NA_NON_THERAPEUTIC |
| Royalties on Trelegy, Tysabri, Evrysdi, Xtandi, Tremfya, Imbruvica, Voranigo, Trodelvy, Imdelltra, Amvuttra and others (35+ marketed products) | Multiple | unclear | NA_NON_THERAPEUTIC |
| Royalty/funding interests in 19-20 licensee-sponsored development-stage candidates (e.g. daraxonrasib, neladalkib, deucrictibant, TEV-'749, TEV-'408) | Multiple | unclear | NA_NON_THERAPEUTIC |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.